Linda Yaccarino has been announced as the new CEO of eMed Population Health, a startup based in Miami that specializes in supporting patients using Ozempic and other GLP-1 drugs for obesity and diabetes treatment. Her leadership is recognized for driving new partnerships and securing deals with employers and government agencies. Yaccarino's exit from X followed two years of challenges with Elon Musk, despite successfully enhancing advertising profitability. She emphasizes the potential to integrate technology, data, and lifestyle to transform the healthcare consumer experience.
Yaccarino, 61, will take over as CEO of Miami-based eMed Population Health, which provides support and resources for patients on Ozempic and other popular GLP-1 drugs used to treat obesity and diabetes.
The healthcare industry has been disrupted by technology, but not yet completely transformed by it," Yaccarino said in a statement.
Yaccarino resigned from X last month after two chaotic years working alongside Musk, who faced intense scrutiny over his work with President Trump's Department of Government Efficiency.
There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before.
Collection
[
|
...
]